Please upgrade your browser.
Mohammad Kazem Moslemia, Mehdi Abedinzadehb
Pfizer Inc won unanimous expert backing for its Inlyta experimental drug for patients with advanced kidney cancer.
Dr. Vogelzang is a founding member and director of the Kidney Cancer Association.
A Business Week Article gives the appearance that FDA might not like this drug, but is it effectiveness or cost that is driving this? FDA recently pulled its approval for Avastin in breast cancer, a drug also used to treat advanced kidney cancer. Some critics thought the cost of the therapy was really at issue.
This fusion protein was capable of inducing DC maturation and interleukin (IL)-12 production in DCs. Interaction of DCs pulsed with CA9-AbOmpA fusion proteins with naive T cells stimulated secretion of IL-2, interferon (IFN)-γ and tumour necrosis factor (TNF)-α in T cells.
What's it like to be a young adult diagnosed with kidney cancer?
The final broadcast of Kidney Cancer News for 2011 examines the importance of advanced surgical techniques in the treatment of renal cancers. It features Dr. Matin who spoke at the Kidney Cancer Association's National Patients and Survivors Conference held in Houston at M. D. Anderson Cancer Center.
Scientists from Nanyang Technological University (NTU) have found a possible link between a popular ingredient in cosmetics and cancer.
The final 2011 edition of Kidney Cancer Journal is now online
This is a dose-escalation study of dasatinib and bevacizumab (Group 1) followed by a randomized study (Group 2). The dose-escalation phase of the study has been completed. Group 2 is now enrolling.
|Powered by NeonCRM|